(REPL) Replimune - Ratings and Ratios
RP1, RP2, RP3, Oncolytic, Immunotherapies
REPL EPS (Earnings per Share)
REPL Revenue
Description: REPL Replimune
Replimune Group Inc is a clinical-stage biotechnology company that is revolutionizing the field of oncology through its innovative oncolytic immunotherapies. By harnessing the power of the immune system, the companys proprietary product candidates aim to combat cancer in a more effective and targeted manner. With a robust pipeline of promising candidates, including RP1, RP2, and RP3, Replimune is poised to make a significant impact in the treatment of various solid tumors.
The companys lead product candidate, RP1, is a genetically engineered version of the herpes simplex virus that is designed to selectively replicate in cancer cells, inducing a potent anti-tumor immune response. RP2 and RP3 build upon this concept, incorporating additional immune-activating proteins to further enhance the bodys natural defenses against cancer. With its cutting-edge technology and promising early-stage results, Replimune is an attractive prospect for investors seeking exposure to the rapidly evolving biotechnology sector.
From a technical analysis perspective, Replimunes stock price has been trending near its 20-day simple moving average (SMA) of $9.46, indicating a potential consolidation phase. The stocks relative strength index (RSI) is not provided, but the average true range (ATR) of 0.77 suggests moderate volatility. Given the current price of $9.27, a potential breakout above the SMA20 or a decline below the SMA50 of $8.75 could signal a significant directional move. With the 52-week high and low range being $14.93 and $6.92, respectively, there is a considerable scope for price movement.
Combining the technical and fundamental data, a forecast for Replimunes stock price can be derived. The companys market capitalization stands at $714.59M, with a negative return on equity (RoE) of -57.98, indicating significant investment in research and development. As RP1, RP2, and RP3 progress through clinical trials, a successful outcome could lead to a substantial increase in the stock price. Assuming a successful trial outcome and subsequent commercialization, a potential price target could be in the range of $15-$20, representing a 60-100% increase from current levels. However, this is contingent upon the companys ability to execute its clinical development plans and navigate the complex regulatory landscape.
It is essential to note that investing in a clinical-stage biotechnology company like Replimune carries inherent risks, including the uncertainty of clinical trial outcomes and regulatory approvals. As such, a thorough evaluation of the companys prospects and risks is crucial before making any investment decisions.
REPL Stock Overview
| Market Cap in USD | 461m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-07-20 |
REPL Stock Ratings
| Growth Rating | -78.0% |
| Fundamental | 30.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -54.4% |
| Analyst Rating | 4.38 of 5 |
REPL Dividends
Currently no dividends paidREPL Growth Ratios
| Growth Correlation 3m | -55.3% |
| Growth Correlation 12m | -68.7% |
| Growth Correlation 5y | -87.2% |
| CAGR 5y | -29.87% |
| CAGR/Max DD 3y | -0.33 |
| CAGR/Mean DD 3y | -0.50 |
| Sharpe Ratio 12m | -0.16 |
| Alpha | -60.81 |
| Beta | 0.684 |
| Volatility | 77.10% |
| Current Volume | 2464.9k |
| Average Volume 20d | 2255.1k |
| Stop Loss | 5.2 (-8.3%) |
| Signal | 0.03 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-280.2m TTM) > 0 and > 6% of Revenue (6% = 88.3k TTM) |
| FCFTA -0.42 (>2.0%) and ΔFCFTA -6.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 24.0k% (prev 11.0k%; Δ 13.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.47 (>3.0%) and CFO -220.1m > Net Income -280.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.94 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (91.5m) change vs 12m ago 32.28% (target <= -2.0% for YES) |
| Gross Margin -192.2% (prev 30.95%; Δ -223.1pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.29% (prev 0.76%; Δ -0.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -34.45 (EBITDA TTM -269.5m / Interest Expense TTM 7.93m) >= 6 (WARN >= 3) |
Altman Z'' -14.05
| (A) 0.75 = (Total Current Assets 413.4m - Total Current Liabilities 59.6m) / Total Assets 469.5m |
| (B) -2.21 = Retained Earnings (Balance) -1.04b / Total Assets 469.5m |
| warn (B) unusual magnitude: -2.21 — check mapping/units |
| (C) -0.54 = EBIT TTM -273.2m / Avg Total Assets 502.2m |
| (D) -7.76 = Book Value of Equity -1.03b / Total Liabilities 132.8m |
| Total Rating: -14.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.13
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.15 = 2.49 |
| 5. Debt/Ebitda -0.19 = -2.50 |
| 6. ROIC - WACC -68.66% = -12.50 |
| 7. RoE -69.34% = -2.50 |
| 8. Rev. Trend 23.97% = 1.20 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -42.24% = -1.06 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of REPL shares?
Over the past week, the price has changed by -6.13%, over one month by +1.98%, over three months by -42.32% and over the past year by -45.79%.
Is Replimune a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of REPL is around 3.73 USD . This means that REPL is currently overvalued and has a potential downside of -34.22%.
Is REPL a buy, sell or hold?
- Strong Buy: 3
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the REPL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.9 | -14.3% |
| Analysts Target Price | 4.9 | -14.3% |
| ValueRay Target Price | 4.1 | -27% |
Last update: 2025-09-04 04:46
REPL Fundamental Data Overview
CCE Cash And Equivalents = 403.3m USD (Cash And Short Term Investments, last quarter)
P/B = 1.3677
Beta = 0.672
Revenue TTM = 1.47m USD
EBIT TTM = -273.2m USD
EBITDA TTM = -269.5m USD
Long Term Debt = 46.8m USD (from longTermDebt, last quarter)
Short Term Debt = 4.04m USD (from shortTermDebt, last quarter)
Debt = 50.8m USD (Calculated: Short Term 4.04m + Long Term 46.8m)
Net Debt = -21.0m USD (from netDebt column, last quarter)
Enterprise Value = 108.0m USD (460.5m + Debt 50.8m - CCE 403.3m)
Interest Coverage Ratio = -34.45 (Ebit TTM -273.2m / Interest Expense TTM 7.93m)
FCF Yield = -184.2% (FCF TTM -198.9m / Enterprise Value 108.0m)
FCF Margin = -13.5k% (FCF TTM -198.9m / Revenue TTM 1.47m)
Net Margin = -19.0k% (Net Income TTM -280.2m / Revenue TTM 1.47m)
Gross Margin = -192.2% ((Revenue TTM 1.47m - Cost of Revenue TTM 4.30m) / Revenue TTM)
Tobins Q-Ratio = -0.10 (set to none) (Enterprise Value 108.0m / Book Value Of Equity -1.03b)
Interest Expense / Debt = 3.93% (Interest Expense 2.00m / Debt 50.8m)
Taxrate = 21.0% (US default)
NOPAT = -273.2m (EBIT -273.2m, no tax applied on loss)
Current Ratio = 6.94 (Total Current Assets 413.4m / Total Current Liabilities 59.6m)
Debt / Equity = 0.15 (Debt 50.8m / last Quarter total Stockholder Equity 336.7m)
Debt / EBITDA = -0.19 (Net Debt -21.0m / EBITDA -269.5m)
Debt / FCF = -0.26 (Debt 50.8m / FCF TTM -198.9m)
Total Stockholder Equity = 404.1m (last 4 quarters mean)
RoA = -59.68% (Net Income -280.2m, Total Assets 469.5m )
RoE = -69.34% (Net Income TTM -280.2m / Total Stockholder Equity 404.1m)
RoCE = -60.58% (Ebit -273.2m / (Equity 404.1m + L.T.Debt 46.8m))
RoIC = -60.66% (NOPAT -273.2m / Invested Capital 450.3m)
WACC = 8.00% (E(460.5m)/V(511.4m) * Re(8.54%)) + (D(50.8m)/V(511.4m) * Rd(3.93%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 84.85 | Cagr: 4.78%
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -198.9m)
EPS Correlation: -42.24 | EPS CAGR: 0.0% | SUE: -1.45 | # QB: False
Revenue Correlation: 23.97 | Revenue CAGR: 0.0%
Additional Sources for REPL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle